Citations

Clear

51 citation(s) found for "Smyth, P".

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
Jhaveri, Komal , Lim, Elgene , Jeselsohn, Rinath , Cynthia, X. , Hamilton, Erika , Osborne, Cynthia R. , Bhave, Manali Ajay, Kaufman, Peter A. , Beck, J. Thaddeus , Manso, Luís , Parajuli, Ritesh , Wang, Hwei-Chung, Tao, Jessica J. , Harnden, Kathleen , Yonemori, Kan , Dhakal, Ajay , Neven, Patrick , Aftimos, Philippe , Pierga, Jean‐Yves , Lu, Yen‐Shen , Larson, Timothy , Jerez, Yolanda , Sohn, Joohyuk , Saura, Cristina , Bardia, Aditya , Sammons, Sarah , Bacchion, Francesca , Li, Yujia , Estrem, Shawn T. , Nguyen, Bastien , Ismail‐Khan, Roohi , Smyth, Lillian M. , Beeram, Muralidhar , Jhaveri, Komal L , Ma, Cynthia , Hamilton, Erika P , Manso Sanchez, Luis , Im, Seock-Ah , Harnden, Kathleen , Yonemori, Kan , Dhakal, Ajay , Neven, Patrick , Aftimos, Philippe , Pierga, Jean-Yves , Lu, Yen-Shen , Larson, Timothy , Sideras, Kostandinos , Sohn, Joohyuk , Kim, Sung-Bae , Saura, Cristina , Bardia, Aditya , Sammons, Sarah L , Li, Yujia , Nguyen, Bastien , Ismail-Khan, Roohi , Smyth, Lillian , Beck, Joseph T , Im, Seock‐Ah , Sideras, Kostandinos , Yuen, Eunice , Rodrik-Outmezguine, Vanessa S.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2024 | Volume: 42 | Issue: 35 | Pages: 4173-4186

10.1200/jco.23.02733 | PMID 39241211 Get It

PURPOSE Imlunestrant is a next-generation oral selective estrogen receptor (ER) degrader designed to deliver continuous ER target inhibition, including in ESR1- mutant breast cancer. This phase Ia/b trial determined the recommended phase II dose (RP2D), safety, pharmacokinetics, and efficacy of imlunestrant, as monotherapy and in combination with targeted therapy, in ER-positive (ER+) advanced breast cancer (ABC) and endometrial endometrioid cancer. The ER+/human epidermal growth factor receptor 2–negative (HER2–) ABC experience is reported here. METHODS An i3+3 dose-escalation design was used, followed by dose expansions of imlunestrant as monotherapy or in combination with abemaciclib with or without aromatase inhibitor (AI), everolimus, or alpelisib. Imlunestrant was administered orally once daily and with the combination partner per label. RESULTS Overall, 262 patients with ER+/HER2– ABC were treated (phase Ia, n = 74; phase Ib, n = 188). Among patients who received imlunestrant monotherapy (n = 114), no dose-limiting toxicities or discontinuations occurred. At the RP2D (400 mg once daily), patients (n = 51) reported grade 1-2 nausea (39.2%), fatigue (39.2%), and diarrhea (29.4%). Patients at RP2D had received previous cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; 92.2%), fulvestrant (41.2%), and chemotherapy (29.4%) for ABC and achieved a median progression-free survival (mPFS) of 7.2 months (95% CI, 3.7 to 8.3). Among patients who received imlunestrant + abemaciclib (n = 42) and imlunestrant + abemaciclib + AI (n = 43), most (69.4%) were treatment-naïve for ABC; all were CDK4/6i-naïve. Patients treated with imlunestrant + everolimus (n = 42)/alpelisib (n = 21) had received previous CDK4/6i (100%), fulvestrant (34.9%), and chemotherapy (17.5%) for ABC. No new safety signals or interactions with partnered drugs were observed. The mPFS was 19.2 months (95% CI, 13.8 to not available) for imlunestrant + abemaciclib and was not reached for imlunestrant + abemaciclib + AI. The mPFS with imlunestrant + everolimus/alpelisib was 15.9 months (95% CI, 11.3 to 19.1)/9.2 months (95% CI, 3.7 to 11.1). Antitumor activity was evident regardless of ESR1 mutation status. CONCLUSION Imlunestrant, as monotherapy or in combination with targeted therapy, had a manageable safety profile with evidence of preliminary antitumor activity in ER+/HER2– ABC.
Postnatal Cardiometabolic Health After Metformin Use in Gestational Diabetes: A Secondary Analysis of the EMERGE Trial
Dunne, Fidelma , Newman, Christine , Alvarez‐Iglesias, Alberto , O’Shea, Paula , Gillespie, Paddy , O’Donnell, Martin , Smyth, Andrew , Gillespie, Paddy , Egan, Aoife, O'Shea, Paula M , Dunne, Fidelma P , Devane, Declan , Egan, Aoife M. , Newman, Christine

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 26, 2024 | Volume: 110 | Issue: 5 | Pages: e1566-e1572

10.1210/clinem/dgae522 | PMID 39056256 Get It

Abstract Aim Women with gestational diabetes mellitus (GDM) display adverse lifetime cardiometabolic health. We examined whether early metformin in GDM could impact cardiometabolic risk factors postpartum. Methods EMERGE, a double-blind, placebo-controlled trial, randomized pregnancies 1:1 to placebo or metformin at GDM diagnosis and followed participants from randomization until 12 ± 4 weeks postpartum. In total, 478 pregnancies were available for postpartum maternal assessment, 237 and 241 assigned to metformin and placebo respectively. Weight (kg), body mass index (BMI) (kg/m2), waist circumference (cm), and blood pressure (mmHg) were measured, infant feeding method documented, and blood specimens drawn for a 75-gram oral glucose tolerance test, fasting insulin, C-peptide, and lipid analysis. Results Despite similar weight and BMI at trial randomization, participants receiving metformin had significantly lower weight (79.5 ± 15.9 vs 82.6 ± 16.9 kg; P = .04) and BMI (29.3 [5.6] vs 30.5 [5.4]; P = .018) at the postpartum visit. However, no difference in weight change from randomization to 12 weeks postpartum was observed between metformin and placebo groups. Overall, 29% (n = 139) of the cohort met criteria for prediabetes or diabetes, with no positive impact with metformin. There were also no differences in measurements of insulin resistance, blood pressure, or lipids between groups. Conclusion Early metformin use in GDM did not impact important cardiometabolic parameters in the early postpartum period despite significant benefits in weight gain and insulin use in pregnancy.
Risankizumab Is Effective for The Management of Crohn’s Disease of the Pouch
Kayal, Maia , Spencer, Elizabeth A. , Smyth, Matthew D. , Raffals, Laura E. , Qazi, Taha , Deepak, Parakkal , Beniwal‐Patel, Poonam , Chang, Shannon, Higgins, Peter , Cross, Raymond, Anderson, Chelsea , Long, Millie D. , Dubinsky, Marla C. , Raffals, Laura , Dubinsky, Marla , Kayal, Maia , Deepak, Parakkal , Qazi, Taha , Herfarth, Hans , Barnes, Edward L.

Mayo Clinic

Inflammatory Bowel Diseases | July 4, 2024 | Volume: 31 | Issue: 3 | Pages: 878-881

10.1093/ibd/izae164 | PMID 39038228 Get It

Lay Summary In this prospective, multicenter observational study of highly refractory patients with Crohn’s disease of the pouch, risankizumab achieved the primary outcome of clinical remission in 50% and the more stringent secondary outcome of antibiotic- and steroid-free remission in 30.8% at 12 weeks.
Percutaneous Coronary Intervention in Acute Myocardial Infarction Patients with Cardiogenic Shock
Forst, Beani, Smyth, Philip J, Kanaan, Christopher , Acharya, Deepak , Smyth, Philip , Forst, Beani, Yang, Eric H. , Lee, Kwan

Mayo Clinic

Journal of the Hong Kong College of Cardiology | June 14, 2024 | Volume: 31 | Issue: 4 | Pages: No page available

10.55503/2790-6744.1533 Get It

Cardiogenic shock is the most common cause of mortality in patients with acute myocardial infarction with an increase in incidence over the last 15-years. Recent classification systems of cardiogenic shock (CS) have improved categorization of patients into subsets of acuity and begun to integrate phenotypes and etiologies in addition to risk modifiers. Early revascularization with PCI or CABG has been the most important advance in the management of AMI-CS patients with improvements in survival. Despite this initial progress, mortality remains high at approximately 40%, with a significant proportion of patients dying of neurological causes, especially in the cohort with cardiac arrest and multi-organ dysfunction despite cardiac recovery. Mechanical circulatory support devices are an attractive strategy to ameliorate the cardio-metabolic spiral but have thus far failed to show survival benefits in randomized trials during revascularization of AMI-CS patients with IABP and ECMO use, although many aspects of their use have yet to be studied, including their role as part of an escalation or bridging strategy along the continuum of CS care. Randomized trials in Impella percutaneous LVAD use are pending. Cardiac arrest patients represent an important cohort with specific challenges of care and familiarity with management including the use of mechanical CPR devices, temperature optimization, MCS use and pharmacotherapy issues are critical to successful outcomes.
Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up
Simonsen, Mikkel Runason , Arboe, Bente , Chanchiri, Iman , Day, Jonathan R , Eyre, Toby A. , Ghesquières, Hervé , Jørgensen, Jennifer Bøgh , Khurana, Arushi , Maquet, Claire, Layshe, Ng, Poulsen, Christian Bjørn , Sima, Andreea, Smedby, Karin Ekstroem, Smyth, Elizabeth , Thanarajasingam, Gita , Xing, Katharine He, Østergaard, Simon , Villa, Diego , Al‐Mashhadi, Ahmed Ludvigsen , Cheah, Chan Y. , Amini, Rose‐Marie , Cerhan, James R. , Clausen, Michael Roost , Gang, Anne Ortved , Habermann, Thomas M. , Hawkes, Eliza A. , Hwang, Steven R. , Opat, Stephen , Pedersen, Martin Bjerregård , Rampotas, Alexandros , Smeland, Knut B. , Smyth, Elizabeth, Trotman, Judith , El‐Galaly, Tarec Christoffer

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 4396-4396

10.1182/blood-2023-173247 Get It

Introduction: Splenic marginal zone lymphoma (SMZL) is a rare, indolent disease. There is no universally accepted standard therapy and long-term outcome data are limited. Rituximab monotherapy is increasingly used over splenectomy in the first-line setting despite a paucity of comparative studies. In the absence of randomized trials, large-scale international real-world data studies are critical to evaluate outcomes of different treatment interventions and to understand the natural history of SMZL in the rituximab-era. Methods: Adult patients with SMZL diagnosed between Jan 1 st 2000 and Dec 31 st 2018 were identified using regional/nationwide population-based registries or hospital registries in Europe, the UK, North America, and Australia. Medical records and pathology reports from eligible patients were reviewed locally by clinicians with specialty experience in hemato-oncology. SMZL cases were required to meet the diagnostic criteria by Matutes et al. Detailed data on clinico-pathological features, comorbidities, treatments (including treatment intention), treatment responses and survival outcomes were entered in a central study database. Overall survival (OS) was defined as time from diagnosis until death from any cause or censoring at last follow-up unless stated otherwise. Event-free survival (EFS) was defined as the time from diagnosis until histological transformation, initiation of new chemotherapy or death from any cause. Survival probabilities were estimated using the Kaplan-Meier estimator. Cumulative risk of transformation was estimated with death as a competing risk. Primary endpoints were 10-year OS and 5-year EFS respectivly. Results: A total of 934 patients from 25 sites were included. Median age at diagnosis was 68 years (IQR 60-76) and 54% were female. Bone marrow involvement was present in 96% (564/590) of those assessed, anemia (Hb <12g/dL for women or <13g/dL for men) in 58%, LDH >UNL in 46%, lymphocytosis (>5 x10 9/L) in 34%, and B-symptoms in 34%. Treatment data were available for 97% of patients. Median follow-up was 9.1 years (range 0-23). Watch and wait was the initial strategy in 28% and 88% of patients received at least one line of treatment during follow-up with the most common being splenectomy (45%), immuno-chemotherapy (19%) or rituximab monotherapy (8%). Fifteen percent received “other” treatments (i.e., combinations of listed therapies and/or radiation). The overall response rate to first-line treatment was 88% (95%CI: 85-90%) with 61% (95%CI: 57-64%) achieving CR. Second line (2L) therapy was needed in 34% during follow-up, 3L in 20% and 4L+ in 9%. The 5-year EFS and OS for all patients were 61% (95%CI: 57-65%) and 77% (95%CI: 74-80%) respectively. The 10-year OS and lymphoma-specific mortality (with non-SMZL deaths as competing risk) estimates were 60% (95%CI: 57-64%) and 11% (95%CI: 9-14%) respectively. The 5-year OS after 2L and 3L were 61% (95%CI: 55-68%) and 51% (95%CI: 42-61%) respectively (figure 1). The 10-year cumulative risk of histological transformation was 17% (95%CI: 13-21%), with 5-year post-transformation OS of 42% (32-54%). At the time of transformation, 60% were chemo-naive and 52% had never been treated for SMZL. The 5-year OS for chemo-naive patients with transformation was 54% (95%CI: 41-71%) versus 24% (95% CI: 13-44%) for transformations after (immuno)chemotherapy (p = 0.01). When comparing patients intended for treatment in first line with splenectomy (n=312) versus rituximab (n=70), patients treated with splenectomy more frequently presented with extra-hilar lymphadenopathy (35% vs 18%), splenomegaly (92% vs 87%) and anemia (64% vs 48%). OS was similar for the two groups (Figure 2, p = 0.53). The 5-year EFS were 63% (95%CI: 57-68%) and 64% (95%CI: 54-77%), respectively (p = 0.31). Conclusions: To date, this is the largest real-world study of SMZL with detailed treatment and outcome data. The study shows that histological transformation was not uncommon with 10-year risk of 17%. However, outcomes for the entire cohort were excellent irrespective of initial treatment and both OS and EFS were similar after first line rituximab versus splenectomy. Long-term survival remained relatively high even following multiple lines of therapy.
Early Metformin in Gestational Diabetes
Dunne, Fidelma , Newman, Christine , Alvarez‐Iglesias, Alberto , Smyth, Andrew , Browne, Marie, O’Shea, Paula , Gillespie, Paddy , Finn, Yvonne , Gaffney, G, Khattak, Aftab, O’Keeffe, Derek T. , O’Donnell, Martin , Egan, Aoife, O'Shea, Paula M , Gillespie, Paddy , Dunne, Fidelma P , Ferguson, John P. , Devane, Declan , Bogdanet, Delia , Kgosidialwa, Oratile , Egan, Aoife M. , Liew, Aaron , Newman, Christine

Mayo Clinic

JAMA | October 3, 2023 | Volume: 330 | Issue: 16 | Pages: 1547

10.1001/jama.2023.19869 | PMID 37786390 Get It

Importance Gestational diabetes is a common complication of pregnancy and the optimal management is uncertain. Objective To test whether early initiation of metformin reduces insulin initiation or improves fasting hyperglycemia at gestation weeks 32 or 38. Design, Setting, and Participants Double-blind, placebo-controlled trial conducted in 2 centers in Ireland (one tertiary hospital and one smaller regional hospital). Participants were enrolled from June 2017 through September 2022 and followed up until 12 weeks’ postpartum. Participants comprised 510 individuals (535 pregnancies) diagnosed with gestational diabetes based on World Health Organization 2013 criteria. Interventions Randomized 1:1 to either placebo or metformin (maximum dose, 2500 mg) in addition to usual care. Main Outcomes And Measures The primary outcome was a composite of insulin initiation or a fasting glucose level of 5.1 mmol/L or greater at gestation weeks 32 or 38. Results Among 510 participants (mean age, 34.3 years), 535 pregnancies were randomized. The primary composite outcome was not significantly different between groups and occurred in 150 pregnancies (56.8%) in the metformin group and 167 pregnancies (63.7%) in the placebo group (between-group difference, −6.9% [95% CI, −15.1% to 1.4%]; relative risk, 0.89 [95% CI, 0.78-1.02]; P = .13). Of 6 prespecified secondary maternal outcomes, 3 favored the metformin group, including time to insulin initiation, self-reported capillary glycemic control, and gestational weight gain. Secondary neonatal outcomes differed by group, with smaller neonates (lower mean birth weights, a lower proportion weighing >4 kg, a lower proportion in the >90% percentile, and smaller crown-heel length) in the metformin group without differences in neonatal intensive care needs, respiratory distress requiring respiratory support, jaundice requiring phototherapy, major congenital anomalies, neonatal hypoglycemia, or proportion with 5-minute Apgar scores less than 7. Conclusion and relevance Early treatment with metformin was not superior to placebo for the composite primary outcome. Prespecified secondary outcome data support further investigation of metformin in larger clinical trials. Trial Registration ClinicalTrials.gov Identifier: NCT02980276 ; EudraCT: 2016-001644-19
EMBER-4: a Phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy in patients with ER+, HER2− early breast cancer with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET
O’Shaughnessy, Joyce , Thomas, Z. M., Young, Stephanie, Ismail‐Khan, Roohi , Smyth, Lillian M. , Harbeck, Nadia , Jhaveri, Komal , André, Fabrice , Goetz, Matthew P. , Martín, Miguel , Bidard, Francois-Clément , Young, S. R., Gnant, Michael

Mayo Clinic

Senologie - Zeitschrift für Mammadiagnostik und -therapie | July 12, 2023 | Volume: 20 | Issue: 02 | Pages: e6-e7

10.1055/s-0043-1769141 Get It

Complex interventions and service innovations: development and application of the COMPLETE framework for patient-centered and justice-oriented design
Bradley, Cory , May, Christine, Smyth, Rachel , Stevenson, Fiona , May, Carl , Hillis, Alyson , Gravenhorst, Katja C , Geng, Elvin Hsing , Gallacher, Katie , Chew-Graham, Carolyn Anne , Lippiett, Kate Alice , Richardson, Alison Mead , Mair, Frances S , MacFarlane, Anne E. , Montori, Víctor M.

Mayo Clinic

No container title available | July 10, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3059427/v1 Get It

AbstractBackground. The field of implementation research has recently seen considerable, and long overdue, interest in equity, with a strong emphasis on recognizing and responding to disparities in care. The COMPLETE (COMPLEx inTErventions and service innovation)framework is intended to support inclusive intervention and service design. The aim is the development of a patient-centered and justice-informed framework for the design of complex healthcare interventions and innovations in service design.Methods. We undertook three studies. (1) We operationalized constructs from sociological theories of inequality, implementation processes, social roles and expectations, to build a Matrix Model of mechanisms that drive the embedding of disparities in complex healthcare interventions and service innovations. (2) We developed patient-centered and justice-informed principles for design that form a Theory of Change that can be applied in intervention and service design. (3) We then linked the Matrix Model and the Theory of Change together with core elements of theories of prefigurative design and research justice, to build a Transformational Design Cycle for complex interventions and service innovations around a set of critical questions about the implications.Results. The COMPLETE framework focuses on the ways health inequalities and inequities are brought into being by systemic mechanisms within health services; are then propagated and normalized through implementation mechanisms; and are then realized and normalized in practice through institutionalized expectations of patients and caregivers. The framework provides tools to resist the naturalization of inequities and inequalities.Conclusion. We developed a framework for intervention and service design that consists of three components: a conceptual model of the translation of social determinants of health through organizational mechanisms that shape patient and caregivers’ lived experience of disparities in health and healthcare; a transformational theory of change; and a set of principles for design that seeks to place restitution for disparities at its center.
Development of an online calculator for the prediction of seizure freedom following pediatric hemispherectomy using the Hemispherectomy Outcome Prediction Scale (HOPS)
Weil, Alexander G. , Dimentberg, Evan , Lewis, Evan , Ibrahim, George M. , Tseng, Chi‐Hong , Chen, Jia‐Shu , Lin, Kao‐Min, Cai, Lixin , Liu, Qingzhu , Lin, Jiuluan , Mathern, Gary W. , Smyth, Matthew D. , O’Neill, Brent R., Dudley, Roy , Ragheb, John , Bhatia, Sanjiv, Delev, Daniel , Zentner, Josef , Bollo, Robert J. , Issabekov, Galymzhan , Zhu, Hongwei , Connolly, Mary , Steinbok, Paul , Zhang, Kai , Weiner, Howard L. , Lapalme‐Remis, Samuel , Tripathi, Manjari , Chandra, P. Sarat , Hader, Walter , Wang, Feng‐Peng , Champagne, Pierre Olivier, Brunette‐Clément, Tristan , Budke, Marcelo , Pérez-Jiménez, María Ángeles, Raftopoulos, Christian , Finet, Patrice, Michel, Pauline, Schaller, Karl , Malone, Christian Cantillano, Pociecha, Juan , Chamorro, Noelia, Muro, Valeria L., Lehe, Marec von , Vieker, Silvia, Gaillard, William D. , Khateeb, Mashael Al, Alotaibi, Faisal , Krayenbühl, Niklaus , Bolton, Jeffrey , Chen, Jia-Shu , Zhou, Wen-Jing , Ramantani, Georgia , Dorfer, Christian , Feucht, Martha , Wong-Kisiel, Lily, Tripathi, Manjari , Sarat Chandra, Poodipedi , von Lehe, Marec , Pearl, Phillip L , Fallah, Aria , Gaillard, William D , Weil, Alexander G , Kola, Olivia , Ramantani, Georgia , Wang, Anthony , Dorfer, Christian , Feucht, Martha , Czech, Thomas , Zhang, Jianguo , Hidalgo, Eveline Teresa , Wong‐Kisiel, Lily C. , Wang, Feng‐Peng, Yao, Yi , Guo, Qiang , Li, Shao‐Chun, Stienen, Martin Nikolaus , Baro, Valentina , Oluigbo, Chima , Pearl, Phillip L. , Fallah, Aria

Mayo Clinic

Epilepsia | June 24, 2023 | Volume: 65 | Issue: 1 | Pages: 46-56

10.1111/epi.17689 | PMID 37347512 Get It

AbstractObjectivesAlthough hemispheric surgeries are among the most effective procedures for drug‐resistant epilepsy (DRE) in the pediatric population, there is a large variability in seizure outcomes at the group level. A recently developed HOPS score provides individualized estimation of likelihood of seizure freedom to complement clinical judgement. The objective of this study was to develop a freely accessible online calculator that accurately predicts the probability of seizure freedom for any patient at 1‐, 2‐, and 5‐years post‐hemispherectomy.MethodsRetrospective data of all pediatric patients with DRE and seizure outcome data from the original Hemispherectomy Outcome Prediction Scale (HOPS) study were included. The primary outcome of interest was time‐to‐seizure recurrence. A multivariate Cox proportional‐hazards regression model was developed to predict the likelihood of post‐hemispheric surgery seizure freedom at three time points (1‐, 2‐ and 5‐ years) based on a combination of variables identified by clinical judgment and inferential statistics predictive of the primary outcome. The final model from this study was encoded in a publicly accessible online calculator on the International Network for Epilepsy Surgery and Treatment (iNEST) website (https://hops‐calculator.com/).ResultsThe selected variables for inclusion in the final model included the five original HOPS variables (age at seizure onset, etiologic substrate, seizure semiology, prior non‐hemispheric resective surgery, and contralateral fluorodeoxyglucose–positron emission tomography [FDG‐PET] hypometabolism) and three additional variables (age at surgery, history of infantile spasms, and magnetic resonance imaging [MRI] lesion). Predictors of shorter time‐to‐seizure recurrence included younger age at seizure onset, prior resective surgery, generalized seizure semiology, FDG‐PET hypometabolism contralateral to the side of surgery, contralateral MRI lesion, non‐lesional MRI, non‐stroke etiologies, and a history of infantile spasms. The area under the curve (AUC) of the final model was 73.0%.SignificanceOnline calculators are useful, cost‐free tools that can assist physicians in risk estimation and inform joint decision‐making processes with patients and families, potentially leading to greater satisfaction. Although the HOPS data was validated in the original analysis, the authors encourage external validation of this new calculator.
Abstract OT1-01-02: EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET
O’Shaughnessy, Joyce , Martín, Miguel, Thomas, Zachary M. , Young, Suzanne R.L., Ismail-Khan, Roohi, Smyth, Lillian M. , Jhaveri, Komal , André, Fabrice , Goetz, Matthew P. , Harbeck, Nadia , Martín, Miguel, Bidard, Francois-Clément , Ismail‐Khan, Roohi , Gnant, Michael

Mayo Clinic

Cancer Research | March 2, 2023 | Volume: 83 | Issue: 5_Supplement | Pages: OT1-01-02-OT1-01-02

10.1158/1538-7445.sabcs22-ot1-01-02 Get It

Abstract Background: Adjuvant ET has been the standard of care for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) EBC. A significant proportion of patients with increased risk still experience disease relapse despite available ET and more optimum ET is needed to prevent patients developing incurable metastatic cancer. Distant recurrence risk ranges from 20% to 40% after 5 years of adjuvant ET, depending on clinicopathological (clin-path) features at diagnosis. Consequently, there is a need to further optimize adjuvant treatment, particularly in those patients who are at increased risk of recurrence. Imlunestrant is an orally bioavailable selective estrogen receptor degrader (SERD) with pure antagonistic properties and the potential to overcome ET resistance. In early phase trials, imlunestrant monotherapy showed favorable safety with pharmacokinetic (PK) exposures exceeding fulvestrant and preliminary efficacy in ER+, HER2- advanced breast cancer patients (EMBER, Jhaveri 2022) along with robust biological/pharmacodynamic activity and tolerability in EBC (EMBER-2, Neven). Trial Design: EMBER-4 is a randomized, open-label, global phase 3 study comparing imlunestrant versus physicians’ choice of ET, in patients who are at an increased risk of recurrence based on clin-path features and who have received 2 to 5 years of standard adjuvant ET. Approximately 6,000 patients will be randomized 1:1 to receive imlunestrant (400 mg daily) for 5 years or physicians’ choice of adjuvant ET (tamoxifen or an aromatase inhibitor, AI, dosed per label). Study treatment duration is 5 years. Males and pre-/peri-menopausal women will receive concomitant treatment with a GnRH agonist if receiving imlunestrant or an AI. Stratification factors include time from initial adjuvant ET, use of prior adjuvant cyclin dependent kinase 4/6 inhibitors, nodal status, menopausal status, and geographic region. Eligibility criteria: Eligible patients are adult males and females (pre-, peri- or postmenopausal) with ER+, HER2- EBC who have completed definitive locoregional therapy and have received 2 to 5 years of prior adjuvant ET without disease recurrence, but who are at increased risk of recurrence based on clin-path features at diagnosis. Prior (neo) adjuvant chemotherapy and/or targeted therapy with a CDK4/6- or PARP- inhibitor is permitted. Study endpoints: The primary endpoint is invasive disease-free survival (IDFS), excluding second non-breast primary invasive cancers. Key secondary endpoints include distant relapse-free survival, overall survival, IDFS including second non-breast primary invasive cancers, safety, PK and patient reported outcomes. Recruitment for EMBER-4 begins globally in Q4 2022. Citation Format: Komal Jhaveri, Joyce O’Shaughnessy, Fabrice Andre, Matthew P. Goetz, Nadia Harbeck, Miguel Martín, Francois-Clement Bidard, Zachary M. Thomas, Suzanne Young, Roohi Ismail-Khan, Lillian M. Smyth, Michael Gnant. EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT1-01-02.